CLINICAL TRIALS PROFILE FOR ORTATAXEL
✉ Email this page to a colleague
Clinical Trials for Ortataxel
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00039156 ↗ | BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma | Unknown status | Theradex | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory non-Hodgkin's lymphoma. |
NCT00039169 ↗ | BAY 59-8862 in Treating Patients With Advanced Kidney Cancer | Unknown status | Theradex | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have advanced kidney cancer. |
NCT00054314 ↗ | BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have non-small cell lung cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Ortataxel
Condition Name
Clinical Trial Locations for Ortataxel
Trials by Country
Clinical Trial Progress for Ortataxel
Clinical Trial Phase
Clinical Trial Sponsors for Ortataxel
Sponsor Name